Zealand Pharma's Four-Asset Metabolism: The Balance Sheet Became the Story
Q3 2026 marked the quarter Zealand stopped sounding like a one-molecule obesity biotech and started sounding like a self-funded platform—just as analysts began asking what it will do with the cash.
ZEAL.CO · Earnings Call · 2026-11-12
The story changed before the numbers did
On 12 November 2026, Zealand Pharma's Q3 call opened with a sentence that would have been hard to imagine a year earlier. Adam Steensberg did not lead with petrelintide's weight-loss percentage. He led with a strategy: Metabolic Frontier 2030. The quarter, he said, “showed what it looks like in motion.” — Adam Steensberg, Chief Executive Officer (CEO) · 2026-11-12 The motion is real: four late-stage assets, a positive EU opinion in short bowel syndrome, a completed cardiovascular safety trial for survodutide, and a cash balance that flips the funding question on its head. The old Zealand story was tolerability versus GLP-1s. The new one is a multi-asset platform with a balance sheet. The financial engine is now the headline. Revenue for the first nine months was DKK 4.5 billion, driven by the Roche collaboration: a DKK 3.7 billion Phase III initiation milestone and a DKK 798 million first-anniversary milestone. The company delivered a DKK 3.5 billion profit and ended September with DKK 13.5 billion of cash. That is not a biotech scraping together a Phase III budget. It is a company that can fund its share of the Roche partnership and still invest in early research.The buyback is the tell. In August 2025, Steensberg was categorical: “You should not expect a share buyback program from Zealand.” — Adam Sinding Steensberg, Chief Executive Officer · 2025-08-14 By Q3 2026, Zealand had completed DKK 1.2 billion of buybacks after the Roche Phase III decision. On this call, CFO Henriette Wennicke left the door only slightly ajar: “no commitments on additional share buybacks for you today.” — Henriette Wennicke, Chief Financial Officer (CFO) · 2026-11-12 That is a capital-allocation pivot, not a permanent policy. It says the board is willing to return cash when the partnership de-risks a milestone, but it is not yet treating the balance sheet as excess capital. Guidance for operating expenses was narrowed to DKK 2.7–3.0 billion, which management framed as cost control rather than a slowdown. Analysts, naturally, asked whether the lower end reflected efficiency or delayed trials; Wennicke declined to break it out.Due to the initiation of the phase III, we will receive the $575 million cash milestone from Roche, which is partly offset by a $175 million payment for the contribution of enicepatide to the petrelintide/enicepatide combination. That is net $400 million in cash, corresponding to approximately DKK 2.6 billion that we will receive in the fourth quarter.